Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn TherapeuticsFHTX -2.19%67 Quick Ratio is 3.36 as of Jun. 2026, which is 34% below its 10-year median of 5.10. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Foghorn Therapeutics ranks worse than 52.45% on this metric.
Foghorn Therapeutics (NAS:FHTX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Foghorn Therapeutics Quick Ratio Related Terms
Foghorn Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Foghorn Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Foghorn Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Foghorn Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics (FHTX) has a Quick Ratio of 3.36 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Foghorn Therapeutics and its competitors. This is 34% below median its historical median of 5.10. Over the past decade, Foghorn Therapeutics' Quick Ratio has ranged from 1.33 to 11.68. According to the industry distribution chart, Foghorn Therapeutics ranks #740 out of 1411 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Foghorn Therapeutics' Quick Ratio too high?
Foghorn Therapeutics' current Quick Ratio of 3.36 is 34% below median its 10-year median of 5.10. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 11.68. The Biotechnology industry median Quick Ratio is 3.69. Foghorn Therapeutics' value of 3.36 is 8.9% below this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #740 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Quick Ratio compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #740 out of 1411 companies for Quick Ratio. This places Foghorn Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.69. Foghorn Therapeutics' value of 3.36 is 8.9% below this benchmark. Historically, Foghorn Therapeutics' own Quick Ratio has ranged from 1.33 to 11.68 over the past decade. While the company's 10-year median is 5.10 vs. the industry median of 3.69, Foghorn Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.69, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current Quick Ratio of 3.36 is 8.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Foghorn Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current Quick Ratio is 3.36, which is 34% below median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current Quick Ratio is 3.36, which is 34% below median its 10-year median of 5.10 and 8.9% below the Biotechnology industry median of 3.69. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Quick Ratio is 3.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
Quick Ratio: 3.36 (34% below median its 10-year median of 5.10)
GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
Industry Position: 8.9% below the Biotechnology median (#740 of 1411)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
